Consolidated Statements of Cash Flows (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 28, 2013	Mar. 29, 2012
Operating activities
Net income	$ 81.2	$ 73.6
Adjustments to reconcile net income to net cash (used in) operating activities
Depreciation expense	39.3	32.9
Amortization expense	1.3	1.2
Amortization of deferred financing fees	1.5	1.6
Employee stock compensation expense	3.7	4.0
Excess tax benefit of share-based payment arrangements		(0.1)
Loss from foreign currency transactions	10.2	(2.4)
Loss on disposition of assets	(0.1)
Deferred taxes	18.6	5.8
Long-term tax(benefit) provision	0.7	(0.2)
Pension and other post retirement benefits, net	(3.3)	(2.1)
Grant Income	(1.6)	(1.4)
Equity in net loss of affiliates	0.2	0.3
Accretion Of Customer Supply Agreement	0.1	0.1
(Gain) from ineffectiveness of hedge contracts	(0.8)	(0.3)
Changes in assets and liabilities
Accounts receivable	(167.7)	(144.4)
Inventory, net	(94.4)	(103.1)
Accounts payable and accrued liabilities	71.4	14.7
Profit sharing/deferred compensation	(10.0)	(7.0)
Advance payments	(12.0)	149.6
Income taxes receivable/payable	2.1	0.5
Deferred revenue and other deferred credits	(0.7)	(11.8)
Other	14.9	0.1
Net cash (used in) operating activities	(45.4)	11.6
Investing Activities
Purchase of property, plant and equipment	(74.4)	(54.2)
Purchase Of Property Plant And Equipment Severe Weather Event	(5.8)
Proceeds from sale of assets	0.1	1.3
Other		(0.7)
Consolidation Of Variable Interest Entity	2.1
Net cash (used in) investing activities	(78.0)	(53.6)
Financing Activities
Proceeds from revolving credit facility		(120.0)
Repayments on revolving credit facility		(120.0)
Principal payments of debt	(2.6)	(2.5)
Excess tax benefit of share-based payment arrangements		0.1
Net cash provided by (used in) financing activities	(2.6)	(2.4)
Effect of exchange rate changes on cash and cash equivalents	(1.6)	0.7
Net (decrease) in cash and cash equivalents for the period	(127.6)	(43.7)
Cash and cash equivalents, beginning of period	440.7	177.8
Cash and cash equivalents, end of period	$ 313.1	$ 134.1